ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Condition : By Disease Heading : Rare Diseases : Urologic Neoplasms


Include trials that are no longer recruiting patients.

108 studies were found. Here are studies 1 to 50.
1.RecruitingSafety and Efficacy of S-8184 in Second Line Treatment of Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium
Condition: Urologic Neoplasms
2.RecruitingSafety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
3.RecruitingStudy of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Conditions: Melanoma; Kidney Neoplasms; Metastases
4.RecruitingCellular Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
5.RecruitingVaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer
6.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
7.RecruitingTreatment of Patients with Metastatic Renal Cell Cancer Using Cultured Tumor-Reactive Lymphocytes and Interleukin-2
Condition: Kidney Neoplasms
8.RecruitingVaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
9.RecruitingBevacizumab With or Without Erlotinib in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
10.RecruitingPEG-Interferon alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Condition: Stage IV Renal Cell Cancer
11.Not yet recruitingSU011248 in the Treatment of Patients with Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
12.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome
13.RecruitingGemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Conditions: transitional cell carcinoma of the bladder; recurrent bladder cancer; stage III bladder cancer; stage IV bladder cancer
14.RecruitingGemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
15.RecruitingErlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Conditions: transitional cell carcinoma of the bladder; stage 0 bladder cancer; stage I bladder cancer
16.RecruitingGenetic Polymorphisms in the RASSF1A Gene in Children With Wilms' Tumor
Conditions: recurrent Wilms' tumor and other childhood kidney tumors; stage I Wilms' tumor; stage II Wilms' tumor; stage III Wilms' tumor; stage IV Wilms' tumor; ...
17.Recruiting17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer
18.RecruitingRNA-Loaded Dendritic Cell Cancer Vaccine
Condition: Renal Cell Carcinoma
19.RecruitingFR901228 in Treating Patients With Advanced Cancer of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
20.RecruitingMonoclonal Antibody Therapy in Treating Patients With Kidney Cancer
Conditions: renal clear cell carcinoma; stage I renal cell cancer; stage II renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
21.RecruitingVaccine Therapy Combined With Interleukin-2 and Interferon alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer
22.RecruitingCelecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Conditions: stage 0 bladder cancer; stage I bladder cancer; stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; ...
23.RecruitingCapecitabine Plus GTI-2040 in Treating Patients With Advanced or Metastatic Renal Cell Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
24.RecruitingA Phase II Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Condition: Stage IV Renal Cell Cancer
25.RecruitingSU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
26.RecruitingFluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer
27.RecruitingSU011248 in Treating Patients With Cytokine-Refractory Metastatic Renal Cell Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
28.RecruitingShort-Term Low-Dose Interferon alfa in Treating Patients With Cancer of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
29.RecruitingFluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
Conditions: Bladder Cancer; Urethral Cancer
30.RecruitingTrial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients with Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
31.RecruitingAvastin With or Without Erlotinib for Treatment of Metastatic Renal Cell Carcinoma
Condition: Renal Cell Cancer
32.RecruitingContinued Use of Monoclonal Antibody ABX-EGF in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Condition: Stage IV Renal Cell Cancer
33.RecruitingHigh-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer
34.RecruitingNeoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
Conditions: stage III bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; anterior urethral cancer; posterior urethral cancer; ...
35.RecruitingDenileukin Diftitox to Treat Advanced Melanoma or Advanced Kidney Cancer
Conditions: Melanoma; Kidney Neoplasms
36.RecruitingTOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium
Conditions: Bladder Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Carcinoma, Transitional Cell
37.RecruitingAG-013736 as Second-Line Therapy in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer
38.Not yet recruitingPaclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
39.RecruitingGenetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
Conditions: Renal Cell Cancer; von Hippel-Lindau Syndrome
40.RecruitingFludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
41.RecruitingStudy of BAY 43-9006 in Patients with Unresectable and/or Metastatic Renal Cell Cancer
Condition: Carcinoma, Renal Cell
42.RecruitingBortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
43.RecruitingNeoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Condition: Bladder Cancer
44.RecruitingInterferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma; recurrent renal cell cancer
45.RecruitingVaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder
Conditions: transitional cell carcinoma of the bladder; stage I bladder cancer
46.RecruitingDoxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
47.RecruitingIrinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
48.RecruitingBortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
Conditions: recurrent bladder cancer; stage IV bladder cancer; metastatic transitional cell cancer of the renal pelvis and ureter; ...
49.RecruitingAdvanced Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell; Kidney Neoplasms
50.RecruitingFR901228 in Treating Patients With Metastatic Renal Cell Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act